← Eichor
Study identifier: NCT02871427 Synced from ClinicalTrials.gov · July 28, 2026
● Terminated

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Condition: Lewy Body Dementia · Dementia With Lewy Bodies · Parkinson's Disease Dementia  ·  Sponsor: Axovant Sciences Ltd.

PhasePhase 2
Planned participants80
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (19)

US120Birmingham, Alabama, United States
US143Little Rock, Arkansas, United States
US114Boca Raton, Florida, United States
US180Maitland, Florida, United States
US154Ocala, Florida, United States
US113Orlando, Florida, United States
US152Ormond Beach, Florida, United States
US107Indianapolis, Indiana, United States
US132Lenexa, Kansas, United States
US103Rochester, Minnesota, United States
US129Lincoln, Nebraska, United States
US101Chapel Hill, North Carolina, United States

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02871427